Capricor Therapeutics (NASDAQ:CAPR) Stock Falls 9.3% After Earnings Miss

Capricor Therapeutics, Inc. (NASDAQ:CAPR) traded down 9.3% during mid-day trading on Tuesday following a dissappointing earnings announcement. The company traded as low as $9.02 and last traded at $8.9320. Approximately 3,207,720 shares were traded during mid-day trading, an increase of 2% from the average session volume of 3,156,311 shares. The stock had previously closed at $9.85.

The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.29).

Analyst Ratings Changes

Several analysts recently weighed in on CAPR shares. Maxim Group lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Cantor Fitzgerald raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Friday, August 14th. HC Wainwright lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, July 27th. B. Riley Financial upgraded Capricor Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $5.00 to $21.00 in a research report on Monday, September 14th. Finally, Roth Capital downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a report on Monday, July 27th. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $29.77.

Institutional Trading of Capricor Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CAPR. Russell Investments Group Ltd. grew its holdings in shares of Capricor Therapeutics by 21.2% during the third quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 3,036 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in Capricor Therapeutics by 151.7% in the 3rd quarter. Commonwealth Equity Services LLC now owns 67,402 shares of the biotechnology company’s stock worth $638,000 after acquiring an additional 40,627 shares in the last quarter. VestGen Advisors LLC purchased a new stake in Capricor Therapeutics in the 3rd quarter worth about $191,000. Oppenheimer & Co. Inc. lifted its stake in Capricor Therapeutics by 169.1% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 203,781 shares of the biotechnology company’s stock worth $1,930,000 after acquiring an additional 128,067 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its position in Capricor Therapeutics by 834.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company’s stock worth $249,000 after acquiring an additional 23,495 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Trading Down 8.7%

The stock has a market capitalization of $595.35 million, a price-to-earnings ratio of -3.88 and a beta of 0.80. The stock has a 50-day simple moving average of $8.09 and a 200 day simple moving average of $19.99.

Capricor Therapeutics Company Profile

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.